Navigation Links
Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
Date:5/14/2008

Conference Call To Be Held Thursday, May 15, 2008 at 9:00 a.m. Eastern Time

HOPKINTON, Mass., May 14 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today reports operational and financial results for the quarter ended March 31, 2008 and provides further information for fiscal year 2008. Recent highlights include:
- Encouraging 12 month interim results from the Phase I/IIa Cethrin(R)

clinical trial in acute spinal cord injury

- Entry into an option agreement which provides the Company with an

option to amend its Cethrin license to lower milestone payments and

royalty rates in exchange for a fee

- Expansion of sites for the first stage of the Parkinson's or Essential

Tremor, or POET-2, Altropane(R) Phase III clinical trial program

- $5 million raised in March 2008

"Our programs continue to show promising progress," said Peter G. Savas, Chairman and Chief Executive Officer of Alseres. "We are encouraged by the unprecedented sensory and motor recovery seen in patients treated with Cethrin in our Phase I/IIa clinical trial. Key opinion leaders with whom we have spoken are highly impressed by the efficacy findings in the study. Armed with these results and after discussions with regulatory authorities and expert advisors, we were able to reduce the planned size of our Phase IIb clinical trial from 200 patients to a maximum of 100 patients providing us with potential time savings and cost reductions."

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO)

"We plan to start this trial in acute cervical spinal cord injury patients in the seco
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
2. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
3. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
4. Alseres Pharmaceuticals, Inc. Raises $5 Million
5. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
6. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
7. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
8. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
9. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
10. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
11. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to The Madison-St. ... Pfizer Inc., Greenstone LLC and Pfizer R&D Cortex District ... defects as a result of using Zoloft during ... filed in St. Clair County Circuit Court (Case No. ... the defendant companies allegedly concealed the risks of serious ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Until now, ... (relational tables) or unstructured data (document stores). SQL products ... products have basically managed the wide assortment of unstructured ... to work with Big Data is with a NoSQL ... the various aspects of all Big Data issues. ...
(Date:8/28/2014)... August 29, 2014 Career Step, an ... released a new video designed to help students and ... coding and billing field. The video details what medical ... for these professionals, and the education requirements for entering ... option that’s often overlooked when people are considering a ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 When David ... and long-time friend of Mark Brnovich, was asked to ... Republican nomination for the Attorney General seat in the ... quickly gathered the support of Cardinal Hall of Fame ... Cardinals Derek Kennard and Mark Walczak. Green, Kennard and ...
(Date:8/28/2014)... banker arrives at the emergency department with complaints ... alcohol every dayoften at business lunches, and at ... decided to quit drinking and had his last ... It,s a common scenario in emergency rooms across ... and develops withdrawal. , Withdrawal is a potentially ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 2Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 3Health News:Scientel Announces Support for SQL Queries and Relational Tables Within Its Gensonix® NoSQL DB 4Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3
... Inhibiting a protein involved in bone metabolism can delay the ... with a particular form of prostate cancer, a researcher will ... Professor Stphane Oudard, Head of ... says that his team,s research on the effects of the ...
... for prostate cancer will be unveiled at the 2011 ... Led by Dr David rsted at the Copenhagen University ... with benign prostate enlargement have an increased risk of ... shows that monitoring prostate-specific antigen levels can be used ...
... News) -- People,s bodies build up vitamin D through exposure ... live in areas of the United States with low sunlight ... who live in the same places. The researchers say ... change. "This study shows that across-the-board vitamin D recommendations just ...
... -- Although some studies have suggested that men can ... their voices, a new study appears to dispel that notion ... women are ovulating by examining changes in their voices over ... Unlike previous studies, the researchers behind the new study ...
... Chronic Disease Alliance (ECDA)1 welcomes the UN High Level Meeting ... killers. "It is a memorable day in the history ... table gives a strong sense of the burden it represents ... challenge for all nations in the world2", declared Professor Michel ...
... 23 (HealthDay News) -- New research suggests that depression ... have survived breast cancer from getting screenings that could ... "Depression can make people more inattentive to potential ... recommendations to reduce their risk," said study researcher Amelie ...
Cached Medicine News:Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 2Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 3Health News:New bone-targeting drug delays onset of metastases in hormone-resistant prostate cancer patients 4Health News:2 new cost-effective ways to predict prostate cancer 2Health News:2 new cost-effective ways to predict prostate cancer 3Health News:2 new cost-effective ways to predict prostate cancer 4Health News:Many Black Men in Cold Climates Lack Vitamin D 2Health News:Non-communicable diseases at the center of UN discussions 2Health News:Depression After Cancer Keeps Some From Follow-Up Care 2
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... Aug. 28, 2014  A candidate Ebola vaccine could be given ... and Mali as early as September, ... aimed at preventing the disease that has killed more than 1,400 ... . Human trials of this candidate vaccine, being co-developed ... to be accelerated with funding from an international consortium in response ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7
... of its commitment to supporting efforts to improve the ... has awarded $1,000 grants to ten health care organizations ... issues. (Logo: http://photos.prnewswire.com/prnh/20100412/DA84842LOGO ) ... the 2010 Beryl Institute Patient Experience grants are: ...
... PITTSBURGH, Oct. 19 Mylan Inc. (Nasdaq: MYL ... preferred stock issuance, the company has declared its quarterly dividend ... of 6.5% and a liquidation preference of $1,000.00 per share) ... of record as of Nov. 1, 2010.  Nov. 15, is ...
Cached Medicine Technology:Patient Experience Research Grants Awarded 2Patient Experience Research Grants Awarded 3
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
9mm Gently Curved Jaws, without lock; in Titanium....
8mm angled shaft with tip at 90 degree angle wtih rounded tear drop point; Tip available in left, right and center; (Right-SQT-225 and Left -SQT-227) In Titanium....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Medicine Products: